A Phase II Randomized Study to Evaluate the Immunologic and Antitumor Activity of Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Advanced HER2-overexpressing Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 09 Apr 2019
Price : $35 *
At a glance
- Drugs AVX 901 (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer
- Focus Pharmacodynamics
- 06 Mar 2019 Status changed from not yet recruiting to recruiting.
- 13 Dec 2018 Planned initiation date changed from 1 Oct 2018 to 1 Feb 2019.
- 24 Aug 2018 New trial record